#	Pagina
attuale pagina	/open-h2020/projects/197195/index.html
-1	/open-h2020/projects/214506/index.html
-2	/open-h2020/projects/209271/results.html
-3	/open-h2020/per-topic/submissions/list/index.html
-4	/open-h2020/per-topic/elaboration/list/index.html
-5	/open-h2020/per-topic/uop/list/index.html
-6	/open-h2020/per-topic/2027/list/index.html
-7	/open-h2020/per-topic/newcotiana/list/index.html
-8	/open-consip/fornitori/2016/profilo-00123770083/index.html
-9	/open-h2020/projects/198410/results.html
-10	/open-h2020/per-topic/variety/list/index.html

Opendata, web and dolomites

OsteomiR

OsteomiR-Test – An In-Vitro Test for the Diagnosis of Osteoporosis and associated Fracture Risk

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

OsteomiR project word cloud

Explore the words cloud of the OsteomiR project. It provides you a very rough idea of what is the project "OsteomiR" about.

blood depends fracture scalability skeletal risk bone demonstrated diet density direct conduct prognosis urgent osteoporotic regulatory biological vitro commercialize good costly consequently performance tests chronic models countries standard predict freedom osteomir ivd structure exercise proprietary micrornas launch strength circulating health specificity creates commercialization mineral market association stress age 2004 prioritize competiveness entry samples 2050 metabolism expectancy superior billion combining readout osteoporosis commercial markets incidence limits 24 fractures diagnostic clinical disease life feasibility select operate successful manufacturing combination strategy systemic 76 tamirna constitute suitable basis meets economic treatment union eur drug approval efficient prevention intended

Project "OsteomiR" data sheet

The following table provides information about the project.

Coordinator	TAMIRNA GMBH Organization address address: LEBERSTRASSE 20/8 city: WIEN postcode: 1110 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Austria [AT]
Project website	http://www.tamirna.com/partners-investors.html
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2015
Funding Scheme	SME-1
Starting year	2015
Duration (year-month-day)	from 2015-07-01 to 2015-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	TAMIRNA GMBH TAMIRNA GMBH Organization address address: LEBERSTRASSE 20/8 city: WIEN postcode: 1110 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	AT (WIEN)	coordinator	50˙000.00

Map

Project objective

TAmiRNA aims to commercialize an in-vitro diagnostic test that is intended to predict fracture-risk in case of osteoporosis. The OsteomiR-Test meets an urgent clinical need by combining superior diagnostic performance with a simple test principle, thus, ensuring cost competiveness, good scalability and commercial success. Osteoporosis is a chronic skeletal disease characterized by systemic loss of bone strength and consequently high incidence of bone fractures. Osteoporotic fractures constitute one of the most common and costly health problems in the European Union (EU): costs related directly to fractures were EUR 24.3 billion in 2004 and will rise to EUR 76.8 billion by 2050 due to increasing life expectancy. Effective fracture prevention can be achieved through exercise, diet and drug treatment, but depends on reliable early prognosis of fracture risk. Currently, bone mineral density and clinical factors are the basis for prognosis of fracture risk. However, the low specificity of these tests limits efficient fracture prevention and creates an urgent clinical need for novel and better tests. The OsteomiR-Test measures a proprietary combination of circulating microRNAs from standard blood samples. The analyzed microRNAs provide a direct readout of bone metabolism, stress and biological age, and have been demonstrated to have a strong association with fracture-risk. It is a robust, easy-to-use test with good scalability. In order to commercialize the OsteomiR-Test, a detailed assessment of a market entry strategy is required. Therefore, TAmiRNA will i) develop health economic models to prioritize EU-countries for market launch, (ii) identify suitable manufacturing and distribution partners, (iii) define a strategy for IVD regulatory approval and, (iv) conduct a freedom-to-operate analysis. The results of this feasibility study will help to select target markets and define the cost structure of the test, and are therefore essential to successful commercialization.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OSTEOMIR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OSTEOMIR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination